🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-519157-10-00
Ongoing Phase I

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

2024-519157-10-00 · tracked via the Priya Life Science EU tracker
Sponsor
AbbVie Deutschland GmbH & Co. KG
Sponsor type
Pharmaceutical company
Therapeutic area
Immune system processes
Decision date
28/08/2025
Enrollment target
18
Sites
Netherlands, France

Condition studied

Systemic Lupus Erythematosus, Sjogren's disease

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-519157-10-00 on CTIS ↗ ← All trials in the EU